Healthcare / BiotechnologyNasdaqCM
$2.97
+0.01 (+0.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.0M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
833.8%
↑Gross Margin
N/A
•Debt/Equity
-0.48
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-178.0M · FCF $-7.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0.00 | — |
| Net Income | $-178.0M | $-178.0M | $-88.4M | $-39.7M | $-113.4M | $-26.7M | $-11.4M | $-18.0M | $-6.3M | $-2.1M | $-1.7M | — | $-2.4M | $-2.1M | $-29945.00 | — |
| EBITDA | $-177.2M | $-177.2M | $-85.9M | $-38.9M | $-112.9M | $-23.3M | $-11.8M | $-10.9M | $-5.3M | $-2.4M | $-2.1M | — | $-2.4M | $-1.7M | — | — |
| EPS | -10.80 | -10.80 | -9.10 | -7.10 | -21.60 | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | -0.48 | -0.48 | 0.03 | 0.12 | 0.10 | — | — | — | — | — | -0.16 | — | 0.03 | -0.43 | — | — |
| Current Ratio | 0.19 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-7.9M | $-7.9M | $-11.0M | $-11.8M | $-15.7M | $-20.7M | $-10.6M | $-9.2M | $-4.4M | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | 833.8% | 833.8% | -67.0% | -85.3% | -156.2% | -15.3% | -6.9% | -10.4% | -4.0% | -139.8% | 272.2% | — | -68.1% | 127.5% | 218.9% | — |
| Valuation | ||||||||||||||||
| P/B | — | — | 9.46 | 4.58 | 11.17 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| EPS Growth | -18.7% | -18.7% | -28.2% | 67.1% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.10 → -10.80
Residual
-87.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.